An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients with Moderate to Severe COVID-19

About this Study

To evaluate the safety and clinical effectiveness of transfusing a unit of banked plasma obtained from patients who have recovered from the novel coronavirus SARS-C0V-2 infection (CCP) with high titers of IgG antibody to this virus transfused into patients with severe or at high risk of progressing to severe coronavirus-induced disease (COVID-19).

Sponsor Protocol ID:2020-0137
IRB Number:2020-0137
Actively Enrolling
Interventional
Phase 1
April 20, 2020
Eligibility Criteria
18 years old
Both Male and Female
No
No
Yes

Inclusion Criteria

CCP Donor:

1. Age > 18;

2. Negative antiHLA antibody screen;

3. Documented historical positive COVID-19 test;

4. Minimum of 28 days since first symptoms and a minimum of 14 days since full clinical recovery;

5. Negative COVID-19 test within 2 days prior to donation; and

6. Able to donate plasma per MS Blood Service guidelines.

CCP Recipient:

1. Aged 18 years of age or older;

2. Clinician-judged serious or life threatening COVID-19.

Exclusion Criteria

None.

(Protocol silent on dual enrollment).

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Participating Locations
University Hospital
Contact Information
Contact Name: Savannah Vann
Phone Number: 601-496-9600
Email: svann@umc.edu
Principal Investigator:Marshall, Gailen D, M.D.Ph.D., M.D., Ph.D.
How to participate in our Clinical Trials